vTv Therapeutics (VTVT) Research & Development (2014 - 2026)

vTv Therapeutics has disclosed Research & Development across 13 years of filings, most recently posting $8.8 million for Q2 2026.

• In Q2 2026, Research & Development rose 113.75% year-over-year to $8.8 million; the TTM figure through Jun 2026 stood at $28.7 million (up 131.43% YoY), while the FY2025 annual figure was $17.9 million, up 54.69% from the prior year.
• Research & Development came in at $8.8 million for Q2 2026 at vTv Therapeutics, down from $9.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $9.0 million in Q1 2026 to a low of $2.1 million in Q4 2023.
• Average Research & Development over 5 years is $4.1 million, with a median of $3.3 million recorded in 2024.
• Year-over-year, Research & Development tumbled 46.06% in 2023 and jumped 217.24% in 2026.
• Over 5 years, Research & Development stood at $4.0 million in 2022, then plunged by 46.06% to $2.1 million in 2023, then increased by 4.49% to $2.2 million in 2024, then soared by 74.93% to $3.9 million in 2025, then jumped by 124.41% to $8.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $8.8 million in Q2 2026, $9.0 million in Q1 2026, and $3.9 million in Q4 2025.